Endoscopic Retrograde Cholangiopancreatography

Part of paid clinical trials in Dallas, Texas.

Sponsor
Methodist Health System
Study ID
NCT07490132
Status
Recruiting
Apply to this trial

Conditions

  • Gastro-Intestinal Disorder

Eligibility Criteria

Sex
ALL
Age
15 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Patients undergoing ERCPs at Methodist Dallas Medical Center — OTHER
    The registry will include all patients who meet registry inclusion. Enrollment will terminate once 25 years of data are captured: January 1, 2000 through December 31, 2025.

Study Details

The risk of post-endoscopic retrograde cholangiopancreatography(ERCP) pancreatitis(PEP) is influenced by patient and procedure-related factors. Strategies to decrease PEP(Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis) are of great importance.

Key Dates

Start date
Feb 28, 2026
Status verified
Feb 2026
Primary completion
Feb 28, 2027
Completion
Feb 29, 2028

Study Design

Enrollment
100 participants (estimated)

Arms

  • Arm: Underwent ERCP
    Underwent ERCP between January 1, 2000 through December 31, 2025

Primary Outcome Measure

Underwent ERCP [ Time Frame: 25 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Methodist Dallas Medical Center- Clinical Research InstituteDallasTexas75203
Colette Ngo Ndjom
[email protected]
214-947-1289
Kavya Mankulangara
[email protected]
214-947-4604

Find similar trials in Dallas, TX

By research site
Methodist Dallas Medical Center- Clinical Research Institute· Dallas, TX

Related Studies